1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


Real-time Estimate Cboe Europe  -  07:27 2022-06-27 am EDT
10756.00 GBX   -0.19%
07:13aMerck, AstraZeneca's Lynparza Obtains EMA's Committee Recommendation as Adjuvant Treatment for Breast Cancer
07:10aEnhertu recommended for approval in the EU by CHMP for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
06:55aAstraZeneca Pharma India Sets Record Date for Fiscal 2022 Final Dividend
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

EU health regulator backs using AstraZeneca COVID shot as booster

05/19/2022 | 11:41am EDT
FILE PHOTO: A woman holds a medical syringe and a small bottle labelled

LONDON, May 19 (Reuters) - The European health regulator on Thursday endorsed the use of AstraZeneca's COVID vaccine, Vaxzevria, as a booster.

The recommendation, made by a committee of the European Medicines Agency (EMA), encompasses adults who have either been previously vaccinated by Vaxzevria or an mRNA vaccine, such as the ones made by Pfizer and BioNTech or Moderna.

The recommendation comes weeks after the EMA backed the use of Pfizer-BioNTech's Comirnaty as a booster for adults who have previously been inoculated with other vaccines.

Vaccine makers, including Pfizer and Moderna, have indicated that most vaccinations this year will be booster shots, or first inoculations for children, which are still gaining regulatory approvals around the world.

It is unclear how many boosters will be needed globally, and many developed countries have already begun to roll them out. In some countries, even second booster campaigns for some high-risk groups have begun.

Meanwhile, vaccine makers are also developing variant-specific vaccines. Earlier this month, the EMA said it hoped to have vaccines adapted to address coronavirus variants, such as Omicron, approved by September.

Although Vaxzevria was AstraZeneca's second best seller last year, it has struggled to compete with mRNA rivals. In late April, AstraZeneca CEO Pascal Soriot asserted that the shot still had a role in fighting the pandemic.

"We believe this vaccine still has a potential, it's very easy to administer and distribute," he said. "The volume in the future will be less because people probably will only need one booster per year and not everybody will take it."

About half of all EU citizens are fully vaccinated and boosted, while 15% of those over 18 have not received even one vaccine shot, said Marco Cavaleri, the EMA's head of biological health threats and vaccines strategy, on May 5.

(Reporting by Natalie Grover in London; Editing by Angus MacSwan)

© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.22% 10750 Delayed Quote.24.31%
BIONTECH SE 1.32% 134.04 Delayed Quote.-48.01%
MODERNA, INC. 0.71% 144.27 Delayed Quote.-43.20%
PFIZER, INC. 2.99% 51.59 Delayed Quote.-12.63%
All news about ASTRAZENECA PLC
07:13aMerck, AstraZeneca's Lynparza Obtains EMA's Committee Recommendation as Adjuvant Treatm..
07:10aEnhertu recommended for approval in the EU by CHMP for patients with HER2-positive meta..
06:55aAstraZeneca Pharma India Sets Record Date for Fiscal 2022 Final Dividend
03:56aAstraZeneca Partner Daiichi Sankyo Says EMA's Committee Backs Approval of Trastuzumab D..
02:18aAstraZeneca's Lynparza, Enhertu Win EU Panel's Backing for Approval in Breast Cancer
12:40aAstraZeneca-Daiichi Sankyo Enhertu Breast Cancer Drug Is Recommended for EU Approval
12:35aAstraZeneca Lynparza Breast Cancer Treatment Is Recommended for EU Approval
06/24AstraZeneca-Merck & Co's Lynparza Receives EU Panel's Positive Opinion for New Indicati..
06/24Sanofi, GSK variant-specific COVID shot found effective against Omicron
06/23AstraZeneca Says Health Canada Expands Approved of Breast Cancer Treatment Enhertu
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2022 43 698 M - -
Net income 2022 4 956 M - -
Net Debt 2022 24 403 M - -
P/E ratio 2022 40,8x
Yield 2022 2,23%
Capitalization 205 B 205 B -
EV / Sales 2022 5,25x
EV / Sales 2023 4,83x
Nbr of Employees 83 100
Free-Float 96,4%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 26
Last Close Price 132,44 $
Average target price 142,04 $
Spread / Average Target 7,25%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC24.31%205 217
JOHNSON & JOHNSON6.56%479 678
PFIZER, INC.-12.63%289 466
ROCHE HOLDING AG-15.91%272 090
ABBVIE INC.12.51%269 202